SavedAdd your journal

Journals / Üroonkoloji Bülteni / 2018 / Cilt: 17 - Sayı: 1

A Rare Side Effect of Intravesical Bacillus Calmette-Guérin Therapy: Reactive Arthritis

İntravezikal Bacillus Calmette-Guérin Tedavisinin Nadir Görülen Yan Etkisi: Reaktif Artrit

Bahattin KIZILGÖK
VOLKAN İZOL
Eren ERKEN
Mustafa Zühtü TANSUĞ
Pages
79–82
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this case report, we present the management of reactive arthritis in a patient treated with intravesical BCG for bladder cancer

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Approximately 70-80% of bladder cancers are superficial tumors and not muscle invasive.
📊
Key Findings & Data:BCG is generally used in high-risk patients and causes local or systemic side effects in less than 5% of patients.
💡
Conclusion & Impact:In this case report, we present the management of reactive arthritis in a patient treated with intravesical BCG for bladder cancer
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Approximately 70-80% of bladder cancers are superficial tumors and not muscle invasive. Complete transurethral resection of the bladder tumour (TUR-BT) is the standard approach to these patients. Intravesical treatments such as adriamycin, doxorubicin, epirubicin, mitomycin-c and bacillus Calmette-Guérin (BCG) may be performed after TUR-BT in order to prevent further recurrence or progression. BCG is generally used in high-risk patients and causes local or systemic side effects in less than 5% of patients. Osteoarticular side effects are very rare and usually manifest as joint pain and arthritis . In this case report, we present the management of reactive arthritis in a patient treated with intravesical BCG for bladder cancer

Özet

1Çukurova Üniversitesi Tıp Fakültesi, Üroloji Anabilim Dalı, Adana, Türkiye2Çukurova Üniversitesi Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Romatoloji Bilim Dalı, Adana, TürkiyeDr. Bahattin Kızılgök1, Dr. Volkan İzol1, Dr. Eren Erken2, Dr. Mustafa Zühtü Tansuğ1İntravezikal Bacillus Calmette-Guérin Tedavisinin Nadir Görülen Yan Etkisi: Reaktif ArtritA Rare Side Effect of Intravesical Bacillus Calmette-Guérin Therapy: Reactive Arthritisklinik vermektedir (10,11). Biz bu olgu sunumumuzda kasa invaziv olmayan mesane kanseri nedeniyle TUR-M yapılan ve sonrasında intravezikal BCG tedavisi uygulanırken reaktif artrit gelişen olgumuzu sunduk.Olgu Sunumu

🔖

Cite This Article

KIZILGÖK, B., İZOL, V., ERKEN, E., TANSUĞ, M. Z. (2018). A Rare Side Effect of Intravesical Bacillus Calmette-Guérin Therapy: Reactive Arthritis. Üroonkoloji Bülteni, Cilt: 17 - Sayı: 1, 79–82. https://ajindex.com/articles/334436

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Torre LA, Bray F, Siegal RL, et al. Global Cancer Statistics, 2012. Ca Cancer J Clın 2015;65:87-108
  2. Cheng L, Neumann RM, Weaver AL, et al. Predicting cancer progression in patients with stage T1 bladder carcinoma. J Clin Oncol 1999;17:3182-3187
  3. Peyromaure M, Zerbib M. T1G3 transitional cell carcinoma of the bladder: recurrence, progression and survival. BJU Int 2004;93:60-63
  4. Iori F, Di Seri M, De Nunzio C, et al. Long-term maintenance bacille Calmette-Guérin therapy in high-grade superficial bladder cancer. Urology 2002;59:414-418
  5. Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus CalmetteGuerin in the treatment of superficial bladder tumors. J Urol 1976;116:180-183
  6. Tinazzi E, Ficarra V, Simeoni S, et al. Reactive arthritis follow-ing BCG immunotherapy for urinary bladder carcinoma: a systematic review. Rheumatol Int 2006;26:481-488
  7. Macía Villa C, Sifuentes Giraldo W, Boteanu A, et al. Reactive Arthritis After the Intravesical Instillation of BCG. Reumatol Clin 2012;8:284-286
  8. Babjuk M, Burger M, Compérat E, et al. EAU Guidelines on Nonmuscle-invasive Bladder Cancer (TaT1 and CIS). European Association of Urology 2018
  9. Clavel G, Grados F, Lefauveau P, Fardellone P. Osteoarticular side effects of BCG therapy. Joint Bone Spine 2006;73:24-28. Epub 2005 Mar 24
  10. Orihuela E, Herr HW, Pinsky CM, Whitmore Jr WF. Toxicity of intravesical BCG and its management in patients with superficial bladder tumors. Cancer 1987;60:326-333
  11. Henares P, Barbadillo C, Cruz M. Artritis reactiva secundaria a inmunoterapia intravesical con bacilo. Semergen 2006;32:176-178
  12. Manzini CU, Bernini L, Elkhaldi N, et al. actilitis and oligoarthritis after BCG immunotherapy in a patient affected by bladder cancer. Reumatismo 2006;58:230-232
  13. Chevrel G, Zech C, Miossec P. Severe uveitis followed by reactive arthritis afterbacillus Calmette-Guérin therapy. J Rheumatol 1999;26:1011
  14. Belmatoug N, Levy-Djebbour S, Appelboom T, et al. Polyarthritis in 4 patients treated with intravesical BCG-therapy for carcinoma of the bladder. Rev Rhum Ed Fr 1993;60:162-166
  15. Pardalidis NP, Papatsoris AG, Kosmaoglou EV, Georganas C. Two cases of acute polyarthritis secondary to intravesicalBCGadjuvant therapy for superficial bladder cancer. Clin Rheumatol 2002;21:536-537.